ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release that at last week's Keystone Symposium on Neurodegenerative Diseases, it presented data that showed greater Alzheimer's disease treatment potential with the company's PMN310.
In her poster presentation, Chief Development Officer Dr. Johanne Kaplan highlighted that ProMIS' PMN310 shows superior selectivity for toxic amyloid beta oligomers in Alzheimer's brain samples and it neutralizes the neurotoxicity and propagation of those oligomers. Further, she showed that PMN310 can be safely given in high doses and, thus, achieve greater therapeutic potency than other amyloid beta-targeting antibodies.
"There was a general consensus for the need to selectively target the propagating forms of toxic proteins in pursuit of disease-modifying therapies. Our data on PMN310 were very well received," Kaplan said in the release.
In podcast Savings Minds' eighth episode, Kaplan expresses her thoughts about the most significant research reviewed at the conference. The podcast is available via Apple Podcasts and Spotify.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
